Vermillion Receives Category 1 CPT Code Approval for OVA1
News Mar 07, 2012
Vermillion, Inc. has reported that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Panel has voted to approve an application for a Category 1 CPT code for its OVA1® test, which is designed to help differentiate benign versus malignant ovarian masses.
The AMA recently disclosed the new code on its website, which will become effective January 1, 2013.
"This is a major achievement for OVA1 and an endorsement for the unmet clinical need addressed by this important triage test," said Gail S. Page, Vermillion's president and chief executive officer.
Page continued, "This approval was supported by several peer-reviewed publications and positive coverage decisions, including Medicare. The new CPT code is a critical step in advancing the commercialization of OVA1, as we believe it will help streamline claims processing and accelerate further coverage and adoption by private payers."
Genomics Researchers Showcase their Applications of Droplet Digital PCR at ASHG 2017 Annual MeetingNews
The sensitivity and reliability of Droplet Digital PCR will be showcased in over a dozen presentations at the American Society of Human Genetics (ASHG) 2017 Annual Meeting.READ MORE
Aqueous Humor Could Help Direct Retinoblastoma TreatmentNews
Study demonstrates that aqueous humor removed during chemotherapy treatment contains tumor DNA, which could be used for a surrogate 'liquid' biopsy.READ MORE
QIAGEN and CENTOGENE to Collaborate in Bioinformatics for Genetic DiseasesNews
Aiding the analysis of hereditary disorders by integrating genomic and clinical databases.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018